<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402018000200129</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2017.06.001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Fixed-dose combination therapy to improve hypertension treatment and control in Latin America]]></article-title>
<article-title xml:lang="es"><![CDATA[Terapia de combinación a dosis fija para mejorar el tratamiento y el control de la hipertensión en América Latina]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Gómez]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meléndez-Gomez]]></surname>
<given-names><![CDATA[Mayra Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[López-Jaramillo]]></surname>
<given-names><![CDATA[Patricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fundación Oftalmológica de Santander (FOSCAL)  ]]></institution>
<addr-line><![CDATA[Floridablanca ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Santander  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,UTE  ]]></institution>
<addr-line><![CDATA[ Quito]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2018</year>
</pub-date>
<volume>88</volume>
<numero>2</numero>
<fpage>129</fpage>
<lpage>135</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402018000200129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402018000200129&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402018000200129&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Hypertension is a major risk factor for cardiovascular disease. Its prevalence is increasing worldwide, and is more common in low and middle-income countries. The effectiveness of hypertension treatment is determined by health cost, awareness, and patients&#8217; compliance with the treatment. People worldwide with an adequate control of hypertension correspond to a very small percentage in low and medium income countries as the Latin America ones. Between the causes to explain these are the low availability, affordability and adherence to treatment with multiple pills. It has been proposed that fixed dose combination therapy could improve the availability, affordability, adherence and control of hypertension. This article aims to review the evidence, showing that fixed dose combination can improve adherence, decrease health cost and improve control of hypertension. Improvement in hypertension control with fixed dose combination could make an important contribution to efforts to fight against the global cardiovascular morbidity and mortality. © 2017 Instituto Nacional de Cardiología Ignacio Chávez. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/).]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La hipertensión es un factor de riesgo importante para el desarrollo de enfermedades cardiovasculares. Su prevalencia está aumentando en todo el mundo, y es más común en los países de medianos a bajos ingresos. La eficacia del tratamiento de la hipertensión está determinada por el costo, el conocimiento y la adherencia de los pacientes con el tratamiento. El control adecuado de la hipertensión corresponde a un porcentaje muy pequeño en países de medianos a bajos ingresos como los países de América Latina. Entre las causas para explicar esto se encuentran la baja disponibilidad, asequibilidad y adherencia al tratamiento con múltiples medicamentos antihipertensivos. Se ha propuesto que la terapia combinada a dosis fija podría mejorar la disponibilidad, asequibilidad, adherencia y control de la hipertensión. Este artículo tiene como objetivo revisar la evidencia que demuestra que la combinación de dosis fija puede mejorar la adherencia, disminuir los costos de salud y mejorar el control de la hipertensión. La mejoría en el control de la hipertensión con terapia de combinación a dosis fija podría aportar una importante contribución a los esfuerzos para combatir la morbilidad y la mortalidad cardiovascular a nivel mundial. © 2017 Instituto Nacional de Cardiología Ignacio Chávez. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0/).]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Combined therapy]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Medication adherence]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
<kwd lng="es"><![CDATA[Terapia combinada]]></kwd>
<kwd lng="es"><![CDATA[Hipertensión]]></kwd>
<kwd lng="es"><![CDATA[Cumplimiento de la medicación]]></kwd>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Vos]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Flaxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2012</year>
<volume>380</volume>
<page-range>2224-60</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Banach]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cushman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is blood pressure control for stroke prevention the correct goal?]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2015</year>
<volume>46</volume>
<page-range>1595-600</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peters]]></surname>
<given-names><![CDATA[SAE]]></given-names>
</name>
<name>
<surname><![CDATA[Huxley]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Woodward]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the sex-pecific associations between systolic blood pressure and the risk of cardiovascular disease: a systematic review and meta-analysis of 124 cohort studies, including 1.2 million individuals.]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2013</year>
<volume>44</volume>
<page-range>2394-401</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baños-González]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cantú-Brito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chiquete]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic blood pressure and functional outcome in patients with acute stroke: a Mexican registry of acute cerebrovascular disease (RENAMEVASC).]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2011</year>
<volume>81</volume>
<page-range>169-75</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kearney]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Whelton]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global burden of hypertension: analysis of worldwide data.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>365</volume>
<page-range>217-23</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Naghavi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<page-range>1459-544</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarki]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Nduka]]></surname>
<given-names><![CDATA[CU]]></given-names>
</name>
<name>
<surname><![CDATA[Stranges]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of hypertension in low- and middle-income countries]]></article-title>
<source><![CDATA[Medicine (Baltimore).]]></source>
<year>2015</year>
<volume>94</volume>
</nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siervo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montagnese]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mathers]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugar consumption and global prevalence of obesity and hypertension: an ecological analysis.]]></article-title>
<source><![CDATA[Public Health Nutr.]]></source>
<year>2014</year>
<volume>17</volume>
<page-range>587-96</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velázquez-Monroy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rosas Peralta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lara Esqueda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and interrelations of noncommunicable chronic diseases and cardiovascular risk factors in Mexico. Final outcomes from the National Health Survey 2000.]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2003</year>
<volume>73</volume>
<page-range>62-77</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meaney]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ceballos-Reyes]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-Salmean]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista Study. Baseline data.]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2013</year>
<volume>83</volume>
<page-range>249-56</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leng]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Socioeconomic status and hypertension.]]></article-title>
<source><![CDATA[J Hypertens.]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>221-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Rangarajan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries.]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2013</year>
<volume>310</volume>
<page-range>959</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Onal]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Erbil]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ozel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of and risk factors for hypertension in adults living in Istanbul]]></article-title>
<source><![CDATA[Blood Press]]></source>
<year>2004</year>
<volume>13</volume>
<page-range>31-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Camacho]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Arbelaez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[DI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Social disparities explain differences in hypertension prevalence, detection and control in Colombia.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2016</year>
<volume>34</volume>
<page-range>2344-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cipullo]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[JFV]]></given-names>
</name>
<name>
<surname><![CDATA[Ciorlia]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension prevalence and risk factors in a Brazilian urban population.]]></article-title>
<source><![CDATA[Arq Bras Cardiol.]]></source>
<year>2010</year>
<volume>94</volume>
<page-range>519-26</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[LBEd]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[SSBEd]]></given-names>
</name>
<name>
<surname><![CDATA[Marcílio]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalência de hipertensão arterial em Adventistas do Sétimo Dia da capital e do interior paulista.]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2012</year>
<volume>98</volume>
<page-range>329-37</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pierin]]></surname>
<given-names><![CDATA[AMG]]></given-names>
</name>
<name>
<surname><![CDATA[Jesus]]></surname>
<given-names><![CDATA[EDS]]></given-names>
</name>
<name>
<surname><![CDATA[Augusto]]></surname>
<given-names><![CDATA[MAdO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variáveis biopsicossociais e atitudes frente ao tratamento influenciam a hipertensão complicada.]]></article-title>
<source><![CDATA[Arq Bras Cardiol.]]></source>
<year>2010</year>
<volume>95</volume>
<page-range>648-54</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Girotto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade]]></surname>
<given-names><![CDATA[SMd]]></given-names>
</name>
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[MAS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalência de obesidade abdominal em hipertensos cadastrados em uma Unidade de Saúde da Família.]]></article-title>
<source><![CDATA[Arq Bras Cardiol]]></source>
<year>2010</year>
<volume>94</volume>
<page-range>754-62</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández-Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Velasco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension in seven Latin American cities: the Cardiovascular Risk Factor Multiple Evaluation in Latin America (CARMELA) study.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>24-34</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ordunez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Niebylski]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension prevention and control in Latin America and the Caribbean.]]></article-title>
<source><![CDATA[J Clin Hypertens]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>499-502</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Burnier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Issues in blood pressure control and the potential role of single-pill combination therapies.]]></article-title>
<source><![CDATA[Int J Clin Pract]]></source>
<year>2009</year>
<volume>63</volume>
<page-range>790-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khatib]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[McKee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shannon]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>387</volume>
<page-range>61-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mills]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Bundy]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global disparities of hypertension prevalence and control clinical perspective.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2016</year>
<volume>134</volume>
<page-range>441-50</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adler]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Prabhakaran]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bovet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reducing cardiovascular mortality through prevention and management of raised blood pressure.]]></article-title>
<source><![CDATA[Glob Heart]]></source>
<year>2015</year>
<volume>10</volume>
<page-range>111-22</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vartiainen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Laatikainen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Peltonen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thirty-five-year trends in cardiovascular risk factors in Finland.]]></article-title>
<source><![CDATA[Int J Epidemiol]]></source>
<year>2010</year>
<volume>39</volume>
<page-range>504-18</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinehall]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hellsten]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Boman]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can a sustainable community intervention reduce the health gap? 10-Year evaluation of a Swedish community intervention program for the prevention of cardiovascular disease.]]></article-title>
<source><![CDATA[Scand J Public Health.]]></source>
<year>2001</year>
<volume>29</volume>
<page-range>59-68</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alwan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[MacLean]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Riley]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Monitoring and surveillance of chronic non-communicable diseases: progress and capacity in high-burden countries.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<page-range>1861-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ebrahim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beswick]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple risk factor interventions for primary prevention of coronary heart disease.]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev.]]></source>
<year>2006</year>
<page-range>CD001561</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christiani]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Byles]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Tavener]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessing socioeconomic inequalities of hypertension among women in Indonesia&#8217;s major cities.]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>2015</year>
<volume>29</volume>
<page-range>683-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cutler]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Lleras-Muney]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding differences in health behaviors by education.]]></article-title>
<source><![CDATA[J Health Econ]]></source>
<year>2010</year>
<volume>29</volume>
<page-range>1-28</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erceg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ivicevi´c-Uhernik]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is there any association between blood pressure and education level? The CroHort study.]]></article-title>
<source><![CDATA[Coll Antropol]]></source>
<year>2012</year>
<volume>36</volume>
<numero>^sSuppl. 1</numero>
<issue>^sSuppl. 1</issue>
<supplement>Suppl. 1</supplement>
<page-range>125-9</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32.</label><nlm-citation citation-type="">
<collab>World Health Organization</collab>
<source><![CDATA[NCD global monitoring frame-work]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Angell]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Asma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A call to action and a life- course strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<page-range>2665-712</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lopez-Jaramillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[DI.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 20×20 Latin American Society of Hypertension target.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>189-90</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[MR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials.]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2003</year>
<volume>326</volume>
<page-range>1427-30</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wald]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination therapy versus monotherapy in reducing blood pressure: meta- analysis on 11,000 participants from 42 trials.]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2009</year>
<volume>122</volume>
<page-range>290-300</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corrao]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Parodi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zambon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2010</year>
<volume>28</volume>
<page-range>1584-90</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Narkiewicz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ESH/ESC Guidelines for the management of arterial hypertension.]]></article-title>
<source><![CDATA[Blood Press]]></source>
<year>2013</year>
<volume>22</volume>
<page-range>193-278</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Jaramillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2013</year>
<volume>31</volume>
<page-range>223-38</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Arshad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Compliance Poulter]]></surname>
<given-names><![CDATA[NR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis.]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2010</year>
<volume>55</volume>
<page-range>399-407</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Jaramillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Coca]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets?]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2016</year>
<volume>68</volume>
<page-range>257-62</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2007</year>
<volume>370</volume>
<page-range>829-40</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2005</year>
<volume>23</volume>
<page-range>2157-72</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jamerson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2008</year>
<volume>359</volume>
<page-range>2417-28</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45.</label><nlm-citation citation-type="journal">
<collab>ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.</collab>
<article-title xml:lang=""><![CDATA[The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2002</year>
<volume>288</volume>
<page-range>2981-97</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlöf]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sever]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT- B).]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>895-906</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlöf]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Devereux]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Kjeldsen]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular morbidity and mortality in the Losartan Intervention For End- point reduction in hypertension study (LIFE): a randomised trial against atenolol.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2002</year>
<volume>359</volume>
<page-range>995-1003</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Niskanen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>353</volume>
<page-range>611-6</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Ekbom]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1999</year>
<volume>354</volume>
<page-range>1751-6</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hedner]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lund-Johansen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<page-range>359-65</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Group]]></surname>
<given-names><![CDATA[SCR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2005</year>
<volume>366</volume>
<page-range>1267-78</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coope]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Warrender]]></surname>
<given-names><![CDATA[TS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomised trial of treatment of hypertension in elderly patients in primary care.]]></article-title>
<source><![CDATA[Br Med J (Clin Res Ed).]]></source>
<year>1986</year>
<volume>293</volume>
<page-range>1145-51</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahlöf]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lindholm]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Hansson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP- Hypertension).]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1991</year>
<volume>338</volume>
<page-range>1281-5</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mancia]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Grassi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zanchetti]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New-onset diabetes and anti- hypertensive drugs.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2006</year>
<volume>24</volume>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bautista]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Vera-Cala]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrante]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A polypill aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.]]></article-title>
<source><![CDATA[Health Aff]]></source>
<year>2013</year>
<volume>32</volume>
<page-range>155-64</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lonn]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López-Jaramillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood-pressure lowering in intermediate-risk persons without cardiovascular disease.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<page-range>2009-20</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lonn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pais]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Blood-pressure and cholesterol lowering in persons without cardiovascular disease.]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<page-range>2032-43</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sever]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dahlof]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Poulter]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2006</year>
<volume>27</volume>
<page-range>2982-8</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lonn]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bosch]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2010</year>
<volume>122</volume>
<page-range>2078-88</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Puska]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Norrving]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global atlas on cardiovascular disease prevention and control]]></article-title>
<source><![CDATA[Geneva: Published by the World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization]]></source>
<year>2011</year>
</nlm-citation>
</ref>
<ref id="B61">
<label>61.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosas Peralta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lara Esqueda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pastelín Hernández]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[National Re-survey of Arterial Hypertension (RENAHTA). Mexican consolidation of the cardiovascular risk factors. National follow-up cohort.]]></article-title>
<source><![CDATA[Arch Cardiol Mex]]></source>
<year>2005</year>
<volume>75</volume>
<page-range>96-111</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abegunde]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE)]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>2005</year>
<volume>83</volume>
<page-range>820-9</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendis]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The availability and affordability of selected essential medicines for chronicl diseases in six low- and middle-income countries.]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>2007</year>
<volume>85</volume>
<page-range>279-88</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Islam]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chow]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2011</year>
<volume>378</volume>
<page-range>1231-43</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Ayala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Baglivo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Latin American guidelines on hypertension*.]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2009</year>
<volume>27</volume>
<page-range>905-22</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Legido-Quigley]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho Lopez]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Balabanova]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patients&#8217; knowledge, attitudes, behaviour and health care experiences on the prevention, detection, management and control of hypertension in Colombia: a qualitative study.]]></article-title>
<source><![CDATA[PLOS ONE.]]></source>
<year>2015</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B67">
<label>67.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherrill]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Halpern]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence.]]></article-title>
<source><![CDATA[J Clin Hypertens.]]></source>
<year>2011</year>
<volume>13</volume>
<page-range>898-909</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hess]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy.]]></article-title>
<source><![CDATA[P&amp;T]]></source>
<year>2008</year>
<volume>33</volume>
<page-range>652-66</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orloff]]></surname>
<given-names><![CDATA[DG.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fixed combination drugs for cardiovascular disease risk reduction: regulatory approach.]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2005</year>
<volume>96</volume>
<page-range>28-33</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beall]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Schwalm]]></surname>
<given-names><![CDATA[J-DR]]></given-names>
</name>
<name>
<surname><![CDATA[Huffman]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Could patents interfere with the development of a cardiovascular polypill?]]></article-title>
<source><![CDATA[J Transl Med]]></source>
<year>2016</year>
<volume>14</volume>
<page-range>242</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
